These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32441531)

  • 1.
    Das A; Martinez Santos JL; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    Cancer Invest; 2020 Jul; 38(6):349-355. PubMed ID: 32441531
    [No Abstract]   [Full Text] [Related]  

  • 2. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
    Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
    Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
    Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
    Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.
    Zang C; Eucker J; Habbel P; Neumann C; Schulz CO; Bangemann N; Kissner L; Riess H; Liu H
    Cell Cycle; 2015; 14(8):1291-9. PubMed ID: 25714853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
    Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
    J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
    Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.
    Yang HW; Kim TM; Song SS; Shrinath N; Park R; Kalamarides M; Park PJ; Black PM; Carroll RS; Johnson MD
    Neoplasia; 2012 Jan; 14(1):20-8. PubMed ID: 22355270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
    Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
    Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.
    Kang CW; Jang KW; Sohn J; Kim SM; Pyo KH; Kim H; Yun MR; Kang HN; Kim HR; Lim SM; Moon YW; Paik S; Kim DJ; Kim JH; Cho BC
    Mol Cancer Ther; 2015 Oct; 14(10):2238-48. PubMed ID: 26208525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.
    Das A; Alshareef M; Henderson F; Martinez Santos JL; Vandergrift WA; Lindhorst SM; Varma AK; Infinger L; Patel SJ; Cachia D
    Clin Transl Oncol; 2020 Jul; 22(7):1138-1145. PubMed ID: 31732915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.